MYELODYSPLASTIC SYNDROME TREATMENT MARKET ANALYSIS

Myelodysplastic Syndrome Treatment Market, by Drug (Lenalidomide, Decitabine, Azacitidine, and Phase 3 Drugs), by Route of Administration (Injection and Oral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Aug 2022
Code : CMI775
Pages :182
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

Global Myelodysplastic Syndrome (MDS) Treatment Market: Key Developments

In July 21 2022, Karyopharm Therapeutics, a biotech company, received new regulatory designations for eltanexor, a novel oral, and Selective Inhibitor of Nuclear Export (SINE) investigational compound being studied for the treatment of myelodysplastic syndromes (MDS). the U.S. Food and Drug Administration (FDA) had granted fast track designation for the development program of eltanexor as monotherapy for the treatment of patients with relapsed or refractory intermediate, high-, or very high-risk MDS. The European Commission (EC) adopted the Committee for Orphan Medicinal Products (COMP) opinion to designate eltanexor as an orphan medicinal product for the treatment of MDS in the European Union (EU). Karyopharm also received orphan drug designation from the Food and Drug Administration in January 2022.

Myelodysplastic Syndrome Treatment Market Report Snapshots